Biocryst Pharmaceuticals (BCRX) Long-Term Investments (2010 - 2026)

Biocryst Pharmaceuticals has reported Long-Term Investments for 17 years, with the latest figure at $20.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments changed 0.1% year-over-year to $20.6 million; the trailing twelve-month figure through Mar 2026 stood at $20.6 million (changed 0.1% YoY), and the FY2025 full-year result was $61.2 million, up 200.96% from the prior year.
• Long-Term Investments for Q1 2026 stood at $20.6 million, down from $61.2 million in the prior quarter.
• The five-year high for Long-Term Investments was $64.3 million in Q2 2024, with the low at $3.4 million in Q1 2023.
• Historically, Long-Term Investments has averaged $26.3 million across 5 years, with a median of $20.4 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 1766.97% — and 2025, when it slumped 84.29%.
• Biocryst Pharmaceuticals' Long-Term Investments stood at $18.1 million in 2022, then plunged by 80.94% to $3.4 million in 2023, then surged by 489.93% to $20.3 million in 2024, then surged by 200.96% to $61.2 million in 2025, then plunged by 66.37% to $20.6 million in 2026.
• The last three Long-Term Investments figures came in at $20.6 million (Q1 2026), $61.2 million (Q4 2025), and $39.7 million (Q3 2025), per Business Quant data.